Abstract: A pharmaceutical composition comprising HLA-A2-expressing mesenchymal stem cells as an effective ingredient and its use in prevention or treatment of inflammatory disease are disclosed. The mesenchymal stem cells expressing HLA-A2 on the surface thereof inhibit the secretion of the inflammatory cytokine TNF-a and increase the expression of the anti-inflammatory markers CD163 and Arg-1, so that the pharmaceutical composition comprising the mesenchymal stem cells as an effective ingredient can be advantageously used for suppressing inflammation or treating inflammatory diseases.

Abstract: A pharmaceutical composition containing hyaluronic acid and mesenchymal stem cells and its use in treating cartilage damage-associated diseases are disclosed. Compared to when hyaluronic acid and mesenchymal stem cells are administered as a mixture, administering mesenchymal stem cells after first administering hyaluronic acid may exhibit superior effects in alleviating disease symptoms in joint tissues affected by arthritis and also decrease the load on knees due to body weight. Accordingly, the pharmaceutical composition may be beneficially used in the treatment of cartilage damage-associated diseases.